recently been recognized as a clinicopathologically distinct disease. To further characterize this disease, here we compared 58 patients with Epstein-Barr virus (EBV)-negative CTL to 48 patients with EBV-positive CTL. The two groups did not differ in histopathology, T-cell receptor (TCR) expression or rearrangement incidences, or survival curves. However, patients with EBV-negative CTL less frequently showed hepatic involvement (P = .007), B symptoms (P = .020), hemophagocytosis (P = .024), and detectable CD4 (P = .002) and CD5 (P = .009). Univariate and multivariate analyses identified three factors that independently predicted favorable survival, onset age <60 years (P = .002), CD5 expression (P = .002), and mixed morphology (P = .013), TCRab was not an independent predictor (P = .30), but was strongly linked with long survivorship among patients younger than 60 years old. A prognostic model incorporating these factors worked well for prognostic delineation, independently of the International Prognostic Index (P = .007 vs P = .082) and Prognostic Index for PTCL (P = .020 vs P = .15). Moreover, this constellation of findings indicated two nodal indolent diseases: CD5 + TCRab (n = 13), and CD5 + NK-cell type lacking TCR expression or clonal TCRc rearrangement (n = 4). The survival curves for these two groups were significantly superior to others (n = 29, P < .001). These diseases appear to be unique in their indolent clinical behavior, and should be managed differently from other diseases.
cell and NK-cell lymphomas/lymphoproliferative disorders (LPDs), including indolent T-cell LPD of the gastrointestinal tract, NK-cell enteropathy/lymphomatoid gastroenteropathy, and primary cutaneous acral CD8 + T-cell lymphoma. 1,2 CM expression has also been noted in some nodal PTCLs. We have reported that nodal CM-positive PTCL (CTL) shows a more aggressive clinical course than CMnegative PTCL, such that CMs constitute a useful biomarker for PTCL. 7 To our knowledge, nodal indolent cytotoxic lymphomas have not been addressed in the past.
There is an accumulation of genetic mutations in TCR signaling molecules in PTCLs, demonstrating that the TCR and its downstream signaling pathway are critically important for their development. [9] [10] [11] [12] [13] [14] [15] TCR comprises an ab or cd heterodimer, and ab is a major component in PTCL as well as T-lymphocytes. 16, 17 PTCL subtypes derived from cd T cells-such as primary cutaneous cd T-cell lymphoma, hepatosplenic T-cell lymphoma, and monomorphic intestinal T-cell lymphoma-show aggressive clinical behavior. 1, 2, [18] [19] [20] [21] [22] We recently documented that nodal EBV-positive CTL has poor prognosis often with a cd phenotype. 7, 8, 23 On the other hand, recent studies shed a light on an indolent cytotoxic T-cell lymphoma/LPD, characterized by a TCRab phenotype and younger onset age, referred to as subcutaneous panniculitis-like T-cell lymphoma with an ab T-cell phenotype. [24] [25] [26] [27] The available data suggest that CMs, EBV infection, and TCRab or cd phenotype status likely affect the pathophysiology of PTCL-NOS. While we previously described the clinicopathological features of nodal EBV-positive CTL, EBV-negative CTL remains uncharacterized. 8, 23 In our present study, we retrospectively investigated the pathological and clinical features of nodal EBV-negative CTL, which led to the identification of nodal indolent CD5-positive diseases predominantly affecting patients younger than 60 years old.
| MATERIALS AND METHODS

| Patients
This study enrolled patients with PTCL-NOS consecutively diagnosed We identified 58 evaluable cases of nodal EBV-negative CTL with paraffin blocks available for analyses, including 39 in our previous study. 8 As a control group, we analyzed data from 48 nodal EBV-positive CTL cases, including 39 previously reported. 8, 23 Our study protocol was approved by the institutional review board of Nagoya University (No.1066-3).
| Histopathology
Tissue samples were fixed in 10% formalin, embedded in paraffin (FFPE). The cases were reviewed by three pathologists (D.Y., S.K., and S.N.), and were divided into four morphologic groups based on cell nuclei shape: centroblastoid, pleomorphic, mixed, and unspecified (Figure 1A-C) . In the centroblastoid group, >50% of the neoplastic cells were large and had oval-to-round vesicular nuclei with fine chromatin, morphologically resembling diffuse large B-cell lymphoma (DLBCL) cells. In the pleomorphic group, over two-thirds of the tumor cells had pleomorphic features with irregular nuclei folding. In the mixed group, the tumors comprised a mixture of medium and large cells. Despite the variation in cell size, cases with mixed morphology showed lower cellular atypia than cases with pleomorphic morphology. Finally, the unspecified group included cases for which the biopsy specimens were too small to reach a good consensus regarding morphology. We also evaluated cells for the presence of elongated nuclei. 
| Immunophenotypic and ISH analysis
5A4
. 28 The reactions were considered positive with a cut-off of 30%
( Figure 1D-F) . Tumor cell and microenviroment PD-L1 expression was considered positive when ≥10% of the tumor cells and nonmalignant stromal cells showed membranous and/or cytoplasmic PD-L1 staining, resepectively. 29, 30 To evaluate the presence of EBV small ribonucleic acids, we subjected formalin-fixed, paraffin-embedded sections to in situ hybridization using EBV-encoded small nuclear early region (EBER) oligonucleotides, as previously reported. 
| TCRc PCR analysis
| RESULTS
| Clinicopathological characteristics of nodal CTLs
Compared to nodal EBV-positive CTL (n = 48), nodal EBV-negative CTL (n = 58) was more commonly associated with favorable clinical parameters at presentation ( Table 1 ). The latter showed lower frequencies of hepatic involvement (10% vs 32%, P = .007); B symptoms (47% vs 72%, P = .022), and hemophagocytosis (13% vs 35%, P = .024) compared to the former.
Treatment for nodal EBV-negative CTL comprised chemotherapeutic regimens with or without anthracycline (46 and 7 patients, respectively). Eight patients underwent high-dose chemotherapy with autologous hematopoietic stem cell transplantation (ASCT).
None of the patients underwent allogeneic transplants. Two exhibited a rapidly lethal clinical course within 3 weeks before any treatment.
Morphological findings did not differ between the EBV-positive and -negative groups. Compared to the latter, the former less frequently showed expression of CD4 (50% vs 19%, P = .002) and CD5 (56% vs 29%, P = .009), but more frequently exhibited CD8 (25% vs 63%, P < .001) and granzyme B (69% vs 95%, P < .001).
Anaplastic lymphoma kinase expression was not detected in our series using the conventional ALK1 antibody. This absence was further verified in 26 EBV-negative cases by using a highly sensitive immunohistochemistry assay. We also did not detect EBV-harboring tumor cells in the present series, although two were accompanied by a small number (5%-15%) of EBV+ B lymphocytes. and lower CR ratio (14% vs 53%, P = .020) than the former, despite their overall overlapping survival curves with median survival times of 8 and 11 months, respectively (Table S1 and Figure S1 ).
| TCR phenotype of nodal CTLs
Among the 47 nodal EBV-negative cases, 23 showed TCRb positivity (ie, TCRab type) ( Table 2 ). Four were determined to be TCRcd type 
| Overall survival for patients with nodal CTLs
The unadjusted OS curves for patients with nodal EBV-positive and EBV-negative CTLs showed an aggressive clinical course, with median survival times of 8 and 11 months, respectively ( Figure 2A ). The survival curves for 24 months after diagnosis overlapped (P = .14), as was previously documented by our group. (Table S2 ). In this cohort, multivariate analysis showed that CD5 was independent from both of IPI and PIT, and that CD5 and mixed appearance, but not TCRab or onset age younger than 60 years, were significant among these 4 variables (Table 3A) . In the analysis limited for nodal EBV -negative CTL cases, variables that predicted poor OS included PIT group 3 or 4 (HR = 5.34, (Table S3) . Interestingly, multivariate analysis revealed that these favorable prognostic factors were independently significant (Table 3B) . Receiving ASCT was not a significant factor predicting favorable outcome (HR = 0.37, P = .099).
| Comparison of the clinicopathological characteristics of nodal EBV-negative CTL patients using a cut-off age of 60 years
After unexpectedly finding that younger onset age was a favorable prognostic indicator, we analyzed the clinicopathological | 2603 characteristics of nodal EBV-negative patients using a cut-off of 60 years (Table 4 ). The available clinical parameters did not significantly differ between groups, except that the younger subgroup was less likely to be in the IPI high-intermediate/high risk group (31% vs 84%, P < .001) and PIT group 3/4 (31% vs 96%, P < .001).
Among EBV-negative CTL cases, the younger subgroup had a significantly more favorable prognosis than the older (median survival of 209 vs 8 months, P < .001) ( Figure 2B ). But, among EBV-positive CTL cases, prognosis did not significantly differ between these two agebased subgroups (median survival of 15 vs 3 months, P = .44).
Detailed This prognostic model was identified as a variable that predicted a favorable outcome (Table S3 , HR = 0.31, P < .001). Multivariate analysis performed for our prognostic model and IPI or PIT revealed that our model was independent from IPI (P = .007 vs P = .082) and PIT (P = .020 vs P = .15, Table 3B ).
| Identification of nodal indolent diseases
Based on the above-described clinicopathologic findings, we retrospectively identified two subgroups defined by their detailed immunophenotype: CD5 + TCRab type (n = 13), and CD5 + NK-cell type without TCR expression or clonal TCRc rearrangement (n = 4).
These patient groups are summarized in Table 5A ,B. They showed survival curves that were significantly superior to other groups (P < .001, Figure 5A ,B). The CD5 + TCRab type group included 7 men and 6 women, with a median age of 59 years (range, 29-79 years) and showed pleomorphic (n = 5), mixed (n = 4), centroblastoid (n = 3), and unspecified (n = 1) appearance. In addition to their constant expression of CD5, TCRab, and CMs, 6 cases were (case # 1-9), seven were alive without disease, and two had died of
T A B L E 3 Multivariate Cox analysis for prognostic factors affecting overall survival of (A) nodal CTL, (B) nodal EBV-negative CTL
Factor Multivariate analysis HR (95% CI) P (A)
Comparison with factors 
| DISCUSSION
Here we reported the clinicopathological characteristics of 58 patients with nodal EBV-negative CTL, the biological behavior and prognostic diversity of which have not previously been described in detail due to the relatively small number of reported cases. 7, 8, 23, 33 To our knowledge, this is the largest published series to date.
Patients with nodal EBV-negative CTL could be divided into two subgroups based on onset age. Patients with an onset age of <60 years (38%) had an unexpectedly favorable clinical course (P < .001). On the other hand, prognosis did not significantly differ between these two age-based subgroups among the EBV-positive cases (P = .44). We initially thought that this more favorable prognosis might be biased due to the therapeutic option of ASCT, which
was not identified as a prognostic indicator in our univariate analysis (HR = 0.37, P = .099). However, among patients with an onset age of <60 years, prognosis did not significantly differ between patients with vs without ASCT (P = .60; Figure S3 ). Rather, the unexpected finding that onset age was a prognostic factor was due to the fact that patients with a younger onset age showed a better response to conventional chemotherapy. ASCT, autologous stem cell transplantation; CR, complete remission; CRP, C-reactive protein; CT, chemotherapy; CTL, cytotoxic molecule(CM)-positive peripheral T-cell lymphoma; cyCD3, cytoplasmic CD3; EBV, Epstein-Barr virus; GI tract, gastrointestinal tract; Hb, hemoglobin; IPI, International Prognostic Index; LDH, lactate dehydrogenase; miPD-L1, microenvironmental PD-L1; NK, natural killer; nPD-L1, neoplastic PD-L1; NR, no response; PIT, prognostic index for PTCL; PR, partial remission; PS, performance status; TCR, T-cell receptor. Interestingly, patients with these TCRab diseases are generally characterized by a young onset age (<60 years), and often show a relatively indolent clinical course. Among the younger patients of our series, TCRab type also appeared to be strongly linked to longer survivorship, although this difference was not statistically significant due to the paucity of enrolled cases. Overall, our findings suggested that nodal EBV-negative CTL is heterogeneous, and that patients with an earlier age of onset and the TCR ab phenotype may constitute a unique subgroup.
F I G U R E 3
We initially reported that nodal EBV-positive CTL was cytopathologically characterized by large lymphoid cells, often showing centroblastoid morphology resembling that of DLBCL. 38 We subsequently reported that over half (56%) of these cases included cells with centroblastoid morphology. 23 In contrast, only 15% of ENKTL cases have cells with centroblastoid morphology (P = .001).
In the present study, nodal EBV-negative and EBV-positive CTLs showed similar incidences of centroblastoid (P = .31), pleomorphic (P = .91), and mixed morphology (P = .092). In nodal EBV-negative CTL, mixed morphology was a good prognostic indicator (HR = 0.29, P = .013), but was not associated with differences in any other clinicopathological parameters.
Analysis of this constellation of clinicopathologic findings-based on CD5, TCRab, mixed appearance, and an onset age younger than 60 years as prognostic indicators-led to the identification of two nodal indolent diseases: CD5 + TCRab type (n = 13), and CD5 + NKcell type without TCR expression or clonal TCRc rearrangement (n = 4). They showed an indolent clinical course that was significantly distinct from the other groups (P < .001). Notably, the CD5 + TCRab type group appeared to be divided into two clinical subgroups based on age-related outcomes even with a cut-off age of 70 years, with young patients showing an indolent course and elderly patients showing an aggressive course (P = .029, Figure S2 ).
We previously emphasized that loss of CD5 expression is the most prognostically significant adverse factor among nodal EBV-positive CTL patients. 8 Pongpruttipan et al 39 Kwong et al 40 recently reported that pembrolizumab is highly effective in patients with relapsed or refractory NK/T-cell lymphoma, and that 80% of these cases showed uniformly strong PD-L1 expression in neoplastic and/or microenvironmental cells, meaning that the therapeutic approach for this EBV-positive lymphoma is revolutionarily changed. In our series, PD-L1 expression on neoplastic and/or microenvironmental cells was detected in 63% of EBV-negative CTL and 59% of EBV-positive CTL cases. However, strong PD-L1 positivity of >50% of neoplastic and/or microenvironmental cells was detected in only two EBV-positive CTL cases (9%), and in no EBVnegative cases. This was less common than the 80% rate reported by Kwong et al. 40 The results could be biased due to difference in the utilized antibodies (clone SP142 vs clone SP263) or the selection of refractory patients in the prior study. Future studies should further investigate this matter.
In conclusion, nodal EBV-negative CTL is heterogeneous, and there may be prognostically indolent subgroups defined by immunophenotype and genotype-ie, CD5 + TCRab and CD5 + NKcell types-which have not previously been highlighted. The clinicopathological and biological diversity of this disease presents diagnostic and therapeutic challenges to pathologists and hematologists, respectively. Much remains unknown about nodal EBV-negative CTL, and further investigation is needed to better understand this disease.
